Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956909 | 0.96 | HTT (0.64) | TSHRRECQLHTTSMN1; SMN2GLA | |
| SCHEMBL29954605 | 0.92 | HTT (0.58) | TSHRRECQLHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6411599 | 0.86 | L3MBTL1 (0.69) | TSHRRECQLHTTHPGDPOLB | |
| SCHEMBL29956307 | 0.84 | ALDH1A1 (0.63) | TSHRHTTSMN1; SMN2HPGDKMT2A | |
| SCHEMBL3758627 | 0.84 | ALDH1A1 (0.63) | TSHRHTTSMN1; SMN2HPGDKMT2A | |
| SCHEMBL10720608 | 0.84 | TSHR (0.69) | TSHRRECQLHTTSMN1; SMN2GLA | |
| SCHEMBL1743230 | 0.83 | ACHE (0.61) | HTTSMN1; SMN2HPGDL3MBTL1TP53BP1 | |
| SCHEMBL30530619 | 0.79 | HTT (0.89) | TSHRRECQLHTTHPGDKMT2A | |
| SCHEMBL1520613 | 0.79 | HTT (0.89) | TSHRRECQLHTTHPGDKMT2A | |
| SCHEMBL10330512 | 0.78 | HTT (0.86) | TSHRRECQLHTTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718265-B1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC (US) | 2015-12-16 | — | — | EP | claimed |
| US-9145366-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | claimed |
| EP-2718265-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | Akebia Therapeutics Inc. (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012170377-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | WO | claimed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | claimed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3290404-A1 | 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF [(5-(HALOPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ALKANOIC ACID DERIVATIVES | Akebia Therapeutics Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3000808-A1 | 5-ARYL OR 5-HETEROARYL SUBSTITUTED 3-HYDROXYPYRIDIN-2-YL-CARBONYLAMINO-ALKANOIC ACID DERIVATIVES AND SALTS THEREOF AS WELL AS THEIR PREPARATION FROM THE RESPECTIVE 3-HYDROXY-PICOLINIC ACID DERIVATIVES | Akebia Therapeutics Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9283222-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2718265-B1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2698062-B1 | Inhibitors of poly(adp-ribose)polymerase | ABBVIE INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2698062-A1 | Inhibitors of poly(adp-ribose)polymerase | Abbvie Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2120579-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8466150-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | TSHR 4199/4885RECQL 432/4885HTT 3393/4885 |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | TSHR 4185/4885RECQL 107/4885HTT 1523/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | TSHR 4185/4885RECQL 107/4885HTT 1523/4885 |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, ALDH7A1 | TSHR 2813/4885RECQL 3672/4885HTT 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.